Literature DB >> 1451353

Combination of interleukin-2 and irradiation in therapy of murine tumors.

N Hunter1, T Nakayama, H Ito, S Woo, L Milas.   

Abstract

Experiments were designed to investigate the therapeutic efficacy of interleukin-2 (IL-2) combined with radiotherapy. The effect of IL-2 and local thoracic irradiation (LTI) was determined on 4-day-old lung micrometastases, generated by i.v. injection of tumor cells into mice. IL-2 alone reduced the number of lung nodules more effectively when given from 1 to 4 than 4 to 7 days after tumor cell injection. The combination of IL-2 and LTI reduced the number of lung nodules more than did the individual treatments alone. When IL-2 therapy was combined with local irradiation of 8-mm leg tumors, there was no change in the TCD50 (radiation dose yielding 50% local tumor control). However, the combination of IL-2 treatment on days 1-4 with irradiation of tumor-bearing legs on day 1 after inoculation of tumor cells reduced the TCD50 by a factor of 1.3. These results show that IL-2 improves tumor radiotherapy, but that the improvement depends on anatomic localization and tumor size at the time of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451353     DOI: 10.1007/bf00133472

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  16 in total

1.  RBE of neutrons generated by 50 MeV deuterons on beryllium for control of artificial pulmonary metastases of a mouse fibrosarcoma.

Authors:  K A Mason; H R Withers
Journal:  Br J Radiol       Date:  1977-09       Impact factor: 3.039

2.  Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

Authors:  L Milas; N Hunter; K Mason; H R Withers
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

3.  Increase in radiosensitivity of lung micrometastases by hyperbaric oxygen.

Authors:  L Milas; N M Hunter; H Ito; W A Brock; L J Peters
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

Review 4.  Recombinant interleukin-2: a biological response modifier.

Authors:  P E Kintzel; K A Calis
Journal:  Clin Pharm       Date:  1991-02

5.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

6.  A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.

Authors:  L E Flaherty; B G Redman; G G Chabot; S Martino; S M Gualdoni; L K Heilbrun; M Valdivieso; E C Bradley
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

7.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

8.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

9.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

10.  Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take.

Authors:  J P Volpe; N Hunter; I Basic; L Milas
Journal:  Clin Exp Metastasis       Date:  1985 Oct-Dec       Impact factor: 5.150

View more
  1 in total

1.  Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice.

Authors:  S S Joshi; L J Messbarger; W Hao
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.